Gefurulimab is under clinical development by Alexion Pharmaceuticals and currently in Phase III for Myasthenia Gravis.

Disclosures: Scott Solomon reports institutional research grants to Brigham and Women’s Hospital from Alexion, Alnylam, Applied Therapeutics, AstraZeneca, Bellerophon, Bayer, BMS, Boston ...

The limitations of currently available therapies for immune thrombocytopenia (ITP) mean that long-term responses are ...

Exercise intolerance is often severe among patients with cardiovascular disease and can impose significant limitations on their physical abilities and quality of life. Medications known as cardiac ...

AstraZeneca has revealed plans to set up a new strategic R&D hub in Cambridge, Massachusetts ... for Alexion – which is currently based across the Charles River in Boston's Seaport District ...

Exercise intolerance is often severe among patients with cardiovascular disease and can impose significant limitations on their physical abilities and quality of life. Medications known as cardiac ...

Finerenone reduced the composite of total first and recurrent heart failure (HF) events (hospitalizations for HF or urgent HF visits) and cardiovascular death in patients with HF and mildly reduced or ...

On August 30, 2024, Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Ltd. (collectively, “Alexion”) and Samsung Bioepis Co. Ltd. (“Samsung Bioepis”) settled their ...

Boston Red Sox manager Alex Cora was ejected in the first inning against the Minnesota Twins in the first game of a ...

Massachusetts-based Alexion said it will begin a phase 3 study investigating UItomirus in COVID-19 patients hospitalised with severe pneumonia or acute respiratory distress syndrome (ARDS).

Boston kids are back running laps on an indoor track at a beloved Roxbury recreation center, a “home” they were displaced ...